Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 4.16 mg - tablet, chewable - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: hyprolose; croscarmellose sodium; iron oxide red; magnesium stearate; hypromellose; iron oxide yellow; macrogol 6000; titanium dioxide; lactose monohydrate; microcrystalline cellulose - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 5.2 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - propolis -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - natural fish oil, quantity: 1000 mg (equivalent: docosahexaenoic acid, qty 120 mg; equivalent: eicosapentaenoic acid, qty 180 mg) - capsule, soft - excipient ingredients: d-alpha-tocopherol; purified water; soya oil; glycerol; gelatin - helps maintain/support healthy cholesterol ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

n-hance pty ltd - epimedium sagittatum,ginkgo biloba,panax ginseng,paullinia cupana,schisandra chinensis,tribulus terrestris,zinc amino acid chelate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

rbk nutraceuticals pty ltd - squalene, quantity: 1 g - capsule, soft - excipient ingredients: soya oil; gelatin; glycerol; d-alpha-tocopherol; purified water - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - eucalyptus fruticetorum,lavandula angustifolia,melaleuca alternifolia,pelargonium graveolens,rosmarinus officinalis,sassafras albidum -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ticarcillin sodium, quantity: 3.3 g (equivalent: ticarcillin, qty 3 g); potassium clavulanate, quantity: 119.2 g (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - timentin is indicated in the treatment of serious infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: septicaemia (and bacteraemia) cases caused by beta-lactamase producing organisms including strains of klebsiella pneumoniae, e.coli, staphylococcus aureus and pseudomonas aeruginosa. lower respiratory infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, haemophilus influenzae and klebsiella pneumoniae. bone and joint infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus. skin and skin structure infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, klebsiella pneumoniae and e. coli. urinary tract infections cases caused by beta-lactamase producing susceptible organisms including strains of e.coli, klebsiella pneumoniae, pseudomonas aeruginosa and staphylococcus au

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g) - injection, powder for - excipient ingredients: - amoxil parenteral is intended for use where the patient's condition precludes the administration of the oral form. it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriological studies, including sensitivity tests, and clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia: (bacterial) h. influenzae; e. coli (see microbiology); p.mirabilis; streptococcus; s. pneumoniae; s. faecalis and salmonella typhi. skin and skin structure: staphylococcus, non-penicillinase-producing; streptococcus; e. coli (see microbiology). respiratory, acute and chronic: haemophilus influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase producing; e. co